Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer

Xing X‐F, Li H, Zhong X‐Y, Zhang L‐H, Wang X‐H, Liu Y‐Q, Jia S‐Q, Shi T, Niu Z‐J, Peng Y, Du H, Zhang G‐G, Hu Y, Lu A‐P, Li J‐Y, Chen S & Ji J‐F 
(2011) Histopathology59, 198–206

[1]  M. A. van de Wiel,et al.  Pla2g2a Attenuates Colon Tumorigenesis in Azoxymethane-Treated C57BL/6 Mice; Expression Studies Reveal Pla2g2a Target Genes and Pathways , 2009, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[2]  M. Weyant,et al.  The Secretory Phospholipase A2 Gene is Required for Gastroesophageal Reflux-Related Changes in Murine Esophagus , 2009, Journal of Gastrointestinal Surgery.

[3]  Y. Collan,et al.  PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  T. Stappenbeck,et al.  Paneth cell development, differentiation, and function: new molecular cues. , 2009, Gastroenterology.

[5]  A. Velcich,et al.  Expression of Pla2g2a prevents carcinogenesis in Muc2‐deficient mice , 2008, Cancer science.

[6]  H. Grabsch,et al.  Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. , 2008, Cancer research.

[7]  R. Cormier,et al.  The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine. , 2008, Frontiers in bioscience : a journal and virtual library.

[8]  D. Graham,et al.  NSAIDs, risks, and gastroprotective strategies: current status and future. , 2008, Gastroenterology.

[9]  Emily J. Greenspan,et al.  Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate , 2008, British Journal of Cancer.

[10]  B. Cummings.  Phospholipase A2 as targets for anti-cancer drugs. , 2007, Biochemical pharmacology.

[11]  S. Keshav.  Paneth cells: leukocyte‐like mediators of innate immunity in the intestine , 2006, Journal of leukocyte biology.

[12]  Sujata Sharma,et al.  Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: structure of the complex formed between phospholipase A2 and diclofenac at 2.7 A resolution. , 2006, Acta crystallographica. Section D, Biological crystallography.

[13]  J. Palazzo,et al.  Diversity in secreted PLA2-IIA activity among inbred mouse strains that are resistant or susceptible to ApcMin/+ tumorigenesis , 2005, Oncogene.

[14]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[15]  O. Sieber,et al.  Genetic basis of variation in adenoma multiplicity in ApcMin/+ Mom1S mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Jon Laye,et al.  Phospholipase A2 expression in tumours: a target for therapeutic intervention? , 2003, Drug discovery today.

[17]  Rui Li,et al.  Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Chan,et al.  Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. , 2002, The Lancet. Oncology.

[19]  Liang Cheng,et al.  Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. , 2002, The American journal of pathology.

[20]  J. Deddens,et al.  Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  William C. Parks,et al.  Secretion of microbicidal α-defensins by intestinal Paneth cells in response to bacteria , 2000, Nature Immunology.

[22]  H. Friess,et al.  Group II and IV phospholipase A2 are produced in human pancreatic cancer cells and influence prognosis , 1999, Gut.

[23]  M. Schwab,et al.  Secretory Type II Phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa , 1998, Oncogene.

[24]  Eric S. Lander,et al.  Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis , 1997, Nature Genetics.

[25]  J. Grönroos,et al.  Expression of group II phospholipase A2 in the human gastrointestinal tract. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[26]  W. Lands.  Metabolism of glycerolipides; a comparison of lecithin and triglyceride synthesis. , 1958, The Journal of biological chemistry.

[27]  K. Jolly,et al.  NSAIDs and Gastrointestinal Cancer Prevention , 2012, Drugs.

[28]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[29]  D. Wilton,et al.  Catalytic and non-catalytic functions of human IIA phospholipase A2. , 2010, Trends in biochemical sciences.

[30]  R. Stradley,et al.  Paneth cell degranulation and lysozyme secretion during acute equine alimentary laminitis , 2004, Histochemistry.

[31]  L. Siracusa,et al.  Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia. , 2002, Genome research.

[32]  M. Selsted,et al.  Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. , 2000, Nature immunology.